Table 3.
Comparision of progression free survival rates
| Variable | 2-year | 5-year | Median (95% CI) | p |
|---|---|---|---|---|
| % | % | |||
| Overall | 4.8 | 3.6 | 4.53 (3.20-5.86) | |
| Age | ||||
| ≤65 | 2.2 | 2.2 | 4.53 (3.43-5.62) | 0.192 |
| >65 | 7.7 | 5.1 | 5.70 (3.29-8.10) | |
| Sex | ||||
| Male | 5.3 | 3.9 | 5.23 (3.91-6.54) | 0.830 |
| Female | - | - | 3.23 (2.12-4.34) | |
| KRAS mutation subtype | ||||
| Non-G12C | 3.8 | - | 5.23 (3.46-6.99) | 0.852 |
| G12C | 5.2 | 3.4 | 4.46 (2.85-6.08) | |
| Brain metastasis | ||||
| No | 5.6 | 3.7 | 4.53 (2.71-6.35) | 0.799 |
| Yes | 3.3 | - | 4.53 (2.96-6.09) |
Kaplan Meier curve, Long rank test, P<0.05 was considered statistically significant.